|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Pathophysiology and biology of peritoneal carcinomatosis显示文摘Peritoneal carcinomatosis represents a devastating form of cancer progression with a very poor prognosis.Its complex pathogenesis is represented by a dynamic process comprising several steps.To the best of our knowledge pathogenesis can be partly explained by 3 major molecular pathways: (1) dissemination from the primary tumor;(2) primary tumor of peritoneum;and (3) independent origins of the primary tumor and peritoneal implants.These are not mutually exclusive and combinations of different mechanisms could occur inside a single case.There are still several aspects which need explanation by future studies.A comprehensive understanding of molecular events involved in peritoneal carcinomatosis is of paramount importance and should be systematically pursued not only to identify novel strategies for the prevention of the condition,but also to obtain therapeutic advances,through the identification of surrogate markers of prognosis and development of future molecular targeted therapies. | Shigeki Kusamura Dario Baratti Nadia Zaffaroni Raffaella Villa Barbara Laterza Maria Rosaria Balestra Marcello Deraco | 2010 | World Journal of Gastrointestinal Oncology2010，2，1： | 8 |
| 2 | Early and long-term postoperative management following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy显示文摘Peritoneal surface malignancies have been traditionally regarded as end-stage conditions amenable to merely palliative options. The combination of aggressive cytoreductive surgery (CRS), involving peritonectomy procedures and multivisceral resections, with intra-operative hyperthermic intra-peritoneal chemotherapy (HIPEC) and/or early postoperative intra-peritoneal chemotherapy (EPIC) to treat the microscopic residual tumor is a new concept. In recent years, promising results have been reported for peritoneal mesothelioma and carcinomatosis of gastrointestinal and gynaecologic origin treated by this combined protocol. However, CRS with HIPEC and/or EPIC is a complex procedure associated with high rates of potentially life-threatening complications. Furthermore, disease progression following comprehensive treatment is not uncommon and represents a relevant cause of treatment failure. The present paper reviews the available information on early postoperative management and long-term follow-up in patients treated with CRS and intraperitoneal chemotherapy. The peculiar clinical and biological alterations that can be expected during an uncomplicated postoperative course, as compared to standard digestive surgery, are discussed. Early recognition and appropriate management of the most common adverse events are addressed, in order to minimize the impact of treatment-related morbidity on survival and quality of life results. Since re-operative surgery with additional HIPEC, has proven to be useful in selected patients with recurrent disease, long-term surveillance aiming at early detection of postoperative disease progression has become a relevant issue. Current results on follow-up investigations are presented. | Dario Baratti Shigeki Kusamura Barbara Laterza Maria Rosaria Balestra Marcello Deraco | 2010 | World Journal of Gastrointestinal Oncology2010，2，1： | 4 |
| 3 | Experience with peritoneal mesothelioma at the Milan National Cancer Institute显示文摘Diffuse malignant peritoneal mesothelioma (DMPM) is an uncommon and rapidly fatal tumor.Therapeutic options have traditionally been limited and ineffective.The biologic and molecular events correlated with poor responsiveness to therapy are still poorly understood.In recent years,an innovative treatment approach involving aggressive cytoreductive surgery (CRS) and perioperative intraperitoneal chemotherapy has reportedly resulted in improved outcome,as compared to historical controls.Since 1995,at the National Cancer Institute (NCI) of Milan (Italy),patients with DMPM have been treated with CRS and hyperthermic intraperitoneal chemotherapy (HIPEC).In the present paper,clinical experiences and basic science investigations on DMPM at Milan NCI are reviewed.Perioperative and long-term outcome results with CRS and HIPEC are presented.Clinico-pathological prognostic factors were investigated by multivariate analysis.The pathologic features and immunohistochemical markers related to DMPM biologic behavior were assessed in a large case-series uniformly treated at our institution.The prevalence and prognostic role of telomere maintenance mechanisms,which account for the limitless cell replicative potential of many malignancies,were studied.The dysregulation of the apoptotic pathways may play a role in the relative chemo-resistance of DMPM and a better understanding of apoptosis-related mechanisms could result in novel targeted therapeutic strategies.On this basis,the expression of survivin and other IAP family members (IAP-1,IAP-2,and X-IAP),the pro-apoptotic protein Smac/DIABLO,and antigens associated with cell proliferation (Ki-67) and apoptosis (caspase-cleaved cytokeratin-18) were analyzed.Finally,analyses of EGFR,PDGFRA and PDGFRB were performed to ascertain if deregulation of RTK could offer useful alternative therapeutic targets. | Marcello Deraco Dario Baratti Antonello Domenico Cabras Nadia Zaffaroni Federica Perrone Raffaella Villa Jenny Jocollè Maria Rosaria Balestra Shigeki Kusamura Barbara Laterza Silvana Pilotti | 2010 | World Journal of Gastrointestinal Oncology2010，2，2： | 3 |
| 4 | Prognostic Analysis of Clinicopathologic Factors in 49 Patients With Diffuse Malignant Peritoneal Mesothelioma Treated With Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion显示文摘 | Marcello Deraco MD Daisuke Nonaka MD Dario Baratti MD Paolo Casali MD Juan Rosai MD Rami Younan MD Andreola Salvatore MD Antonello D. Cabras AD MD Shigeki Kusamura MD | 2006 | Annals of Surgical Oncology2006，，2： | 2 |
| 5 | Peritonectomy and Intraperitoneal Hyperthermic Perfusion (IPHP): A Strategy That Has Confirmed its Efficacy in Patients with Pseudomyxoma Peritonei显示文摘 | Marcello Deraco Dario Baratti Maria Grazia Inglese Biagino Allaria Salvatore Andreola Cecilia Gavazzi Shigeki Kusamura | 2004 | Annals of Surgical Oncology2004，，： | 2 |
| 6 | Prognostic Value of Circulating Tumor Markers in Patients with Pseudomyxoma Peritonei Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy显示文摘 | Dario Baratti MD Shigeki Kusamura MD PhD Antonia Martinetti MD Ettore Seregni MD Barbara Laterza MD Daniela G. Oliva MD Marcello Deraco MD | 2007 | Annals of Surgical Oncology2007，，8： | 2 |
| 7 | Impact of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy on Systemic Toxicity显示文摘 | Shigeki Kusamura MD PhD Dario Baratti MD Rami Younan MD Barbara Laterza MD Grazia Daniela Oliva MD Pasqualina Costanzo MD Myriam Favaro MD Cecilia Gavazzi MD Federica Grosso MD Marcello Deraco MD | 2007 | Annals of Surgical Oncology2007，，9： | 1 |
| 8 | Circulating CA125 in Patients with Peritoneal Mesothelioma Treated with Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion显示文摘 | Dario Baratti MD Shigeki Kusamura MD Antonia Martinetti MD Ettore Seregni MD Daniela G. Oliva MD Barbara Laterza MD Marcello Deraco MD | 2007 | Annals of Surgical Oncology2007，，2： | 1 |
| 9 | Bowel Complications in 203 Cases of Peritoneal Surface Malignancies Treated With Peritonectomy and Closed-Technique Intraperitoneal Hyperthermic Perfusion显示文摘 | Rami Younan MD Shigeki Kusamura MD Dario Baratti MD Grazia Daniela Oliva MD Pasqualina Costanzo MD Myriam Favaro MD Cecilia Gavazzi MD Marcello Deraco MD | 2005 | Annals of Surgical Oncology2005，，11： | 1 |
| 10 | Peritonectomy and Intraperitoneal Hyperthermic Perfusion (IPHP): A Strategy That Has Confirmed its Efficacy in Patients with Pseudomyxoma Peritonei显示文摘 | Marcello Deraco MD Dario Baratti MD Maria Grazia Inglese MD Biagino Allaria MD Salvatore Andreola MD Cecilia Gavazzi MD Shigeki Kusamura MD | 2004 | Annals of Surgical Oncology2004，，4： | 1 |
| 11 | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: Multi-institutional phase-II trial显示文摘 | Marcello Deraco Shigeki Kusamura Salvatore Virzì Francesco Puccio Antonio Macrì Ciro Famulari Massimiliano Solazzo Serena Bonomi Domenico Rosario Iusco Dario Baratti | 2011 | Gynecologic Oncology2011，，2： | 1 |
| 12 | Pseudomyxoma Peritonei: Biological Features Are the Dominant Prognostic Determinants After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy显示文摘 | Dario Baratti Shigeki Kusamura Daisuke Nonaka Antonello Domenico Cabras Barbara Laterza Marcello Deraco | 2009 | Annals of Surgery2009，，2： | 1 |
| 13 | Diffuse malignant peritoneal mesothelioma: Long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC)显示文摘 | Dario Baratti Shigeki Kusamura Antonello Domenico Cabras Rossella Bertulli Ionut Hutanu Marcello Deraco | 2013 | European Journal of Cancer2013，，： | 1 |
| 14 | The Role of Perioperative Systemic Chemotherapy in Diffuse Malignant Peritoneal Mesothelioma Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy显示文摘 | Marcello Deraco Dario Baratti Ionut Hutanu Rossella Bertuli Shigeki Kusamura | 2013 | Annals of Surgical Oncology2013，，4： | 1 |
| 15 | Prognostic Analysis of Clinicopathologic Factors in 49 Patients With Diffuse Malignant Peritoneal Mesothelioma Treated With Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion显示文摘 | Marcello Deraco MD Daisuke Nonaka MD Dario Baratti MD Paolo Casali MD Juan Rosai MD Rami Younan MD Andreola Salvatore MD Antonello D. Cabras AD MD Shigeki Kusamura MD | 2006 | Annals of Surgical Oncology2006，，2： | 1 |
| 16 | PSOGI和ESSO之间的教育联盟:欧洲大陆的培训经验和模式显示文摘既往腹膜表面肿瘤学科的培训常通过医师的个人自学实现,鉴于目前这一学科的发展,对该领域专家的需求越来越大,因此有必要形成组织化的教育和培训方式。在欧洲外科肿瘤学会(ESSO)和国际腹膜表面恶性肿瘤学会(Peritoneal Surface Oncology Group International,PSOGI)的共同努力下,欧洲腹膜表面肿瘤学院(ESPSO)于2014年成立。该组织基于导师制的腹膜表面肿瘤学培训项目,已获得欧洲认证。自该项目成立年至2021年7月14日,共有42名外科医生从该培训项目毕业,其中大多数来自欧洲,也有部分非欧洲的毕业生,这使得该项目具有全球影响力。目前,已有35名候选学员已在欧洲和非欧洲培训中心完成注册。鉴于当前培训的成功,该项目正在加速发展,目前不断有新的教员加入以及新的培训活动开展。欧洲腹膜表面肿瘤学学院成功建立了一个结构化的基于导师制的培训项目,并获得了专业认证。得益于来自全球的大量毕业生和候选学员,使该项目获得了预期的声望,满足了学员的需求,并为本培训项目下一步计划的实施提供了保障。本文主要介绍此培训项目方案。 | Santiago Gonzalez-Moreno Marcello Deraco Shigeki Kusamura Lana Bijelic Ana Galan Frederic Bibeau Clarisse Dromain Laura Lambert Winston Liauw Paul HSugarbaker 高超(翻译) 李雁(审校) | 2022 | 中国肿瘤临床2022，49，24： | 0 |
| 17 | 恶性腹膜间皮瘤在米兰国家癌症中心的治疗进展显示文摘弥漫性恶性腹膜间皮瘤(diffuse malignant peritoneal mesothelioma,DMPM)是一种源自腹膜间皮细胞、高度恶性的罕见原发性恶性肿瘤,本文对DMPM的定义、诊断、患者管理流程、米兰国家癌症中心肿瘤细胞减灭术(cytoreductive surgery,CRS)联合腹腔热灌注化疗(hyperthermic intraperitoneal chemotherapy,HIPEC)治疗数据、围手术期化疗对患者预后影响、多囊型腹膜间皮瘤治疗建议、乳头状腹膜间皮瘤治疗建议等进行概述。对本中心DMPM认识与治疗经验进行介绍。随着对这类肿瘤疾病的临床特征和生物学特性进行广泛研究,发现可切除性DMPM应接受CRS+HIPEC,可能会改变患者的自然病程。 | Marcello Deraco 杨智冉(翻译) 李雁(审校) | 2022 | 中国肿瘤临床2022，49，24： | 0 |
| 18 | Decellularized extracellular matrix as scaffold for cancer organoid cultures of colorectal peritoneal metastases显示文摘Peritoneal metastases (PM) from colorectal cancer (CRC) are associated with poor survival. The extracellular matrix (ECM) plays a fundamental role in modulating the homing of CRC metastases to the peritoneum. The mechanisms underlying the interactions between metastatic cells and the ECM, however, remain poorly understood, and the number of in vitro models available for the study of the peritoneal metastatic process is limited. Here, we show that decellularized ECM of the peritoneal cavity allows the growth of organoids obtained from PM, favoring the development of three-dimensional (3D) nodules that maintain the characteristics of in vivo PM. Organoids preferentially grow on scaffolds obtained from neoplastic peritoneum, which are characterized by greater stiffness than normal scaffolds. A gene expression analysis of organoids grown on different substrates reflected faithfully the clinical and biological characteristics of the organoids. An impact of the ECM on the response to standard chemotherapy treatment for PM was also observed. The ex vivo 3D model, obtained by combining patient-derived decellularized ECM with organoids to mimic the metastatic niche, could be an innovative tool to develop new therapeutic strategies in a biologically relevant context to personalize treatments. | Luca Varinelli Marcello Guaglio Silvia Brich Susanna Zanutto Antonino Belfiore Federica Zanardi Fabio Iannelli Amanda Oldani Elisa Costa Matteo Chighizola Ewelina Lorenc Simone P.Minardi Stefano Fortuzzi Martina Filugelli Giovanna Garzone Federica Pisati Manuela Vecchi Giancarlo Pruneri Shigeki Kusamura Dario Baratti Laura Cattaneo Dario Parazzoli Alessandro Podestà Massimo Milione Marcello Deraco Marco A.Pierotti Manuela Gariboldi | 2022 | Journal of Molecular Cell Biology2022，14，11： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员